We caught up with Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to discuss the results of the phase 2B study of roflumilast cream in adults with chronic plaque psoriasis (ClinicalTrials.gov identifier: NCT03638258).
1. What are the limitations of current topical therapies for chronic plaque psoriasis? (0:06)
2. What is the mechanism of action of roflumilast and what are its advantages compared with other PDE4 inhibitors used in dermatology? (1:03)
3. Could you tell us a little about the ARQ-151 201 study and its efficacy and safety findings? (1:47)
4. Tell us more about the effect of roflumilast on patient-reported outcomes. (2:48)
5. What were the limitations of this study and what future studies are planned? (3:49)
Disclosures: Dr Gold Stein reports the following relationships – Arcutis: Investigator, Advisor; Dermavant: Investigator, Advisor; Leo Pharma: Investigator, Advisor; Ortho Derm: Investigator, Advisor; and Pfizer: Investigator, Advisor, Speaker.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the EADV 2020 Virtual Congress.
Share this Video
Related Videos In Psoriasis
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Linda Stein Gold, EADV 2022: Quality of Life and Clinical Efficacy Findings from PSOARING 1 and PSOARING 2
PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) were two phase 3 trials investigating tapinarof cream, a novel, steroid-free, AhR modulating agent for the treatment of plaque psoriasis. It was a pleasure to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) around the aims, design, endpoints and quality of life and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!